2011 will produce the 10 blockbuster drug class.docVIP

 PAGE \* MERGEFORMAT 5 2011 will produce the 10 blockbuster drug class In the next few months, FDA approval of new drugs will be made to wait for the most important decision this year. These drugs include half a century, developed the first drug treatment for systemic lupus erythematosus, with “blockbuster” potential Anticoagulants and controversial weight-loss drugs, and other products. FDA’s decision will determine the fate of these products in the market - either hard, or fast becoming a “blockbuster.” NO.1 Benlysta Developer: Human Genome Sciences (HGS and GlaxoSmithKline Market Potential: 30 billion to $ 4,000,000,000 Not long ago, FDA rejected the company’s hepatitis C HGS drugs Zalbin applications that end, Novartis and HGS in the termination of the cooperation, so as to leave the company sold 2.3 billion gap. Now, HGS would like to do it alone Zalbin project. But HGS stock was not affected, because all the investors all head off to the HGS locked in the treatment of systemic lupus erythematosus FDA (SLE on the approval of new drugs Benlysta. HGS sales forecast Benlysta up to 4.1 billion U.S. dollars annually, Benlysta in the United States has about 30 million potential consumer groups, the world will be more. Benlysta HGS appears to be the role of conversion from a pure developer to become a marketing persons. Year, FDA decided to Benlysta for priority review, the analysts also Benlysta be approved as one of the best-selling drugs with confidence. NO.2 Bydureon Developer: Eli Lilly, Amylin, and Alkermes Market Potential: 10 billion to $ 6,000,000,000 Develop a new generation of diabetes drugs is not an easy thing. Roche Diabetes Drug Taspoglutide setbacks is a painful lesson. GLP-1 drugs market growth is expected to receive the lion’s share, and analysts now agree that the Byetta diabetes cure long-term 1 week 1 will be a new version of Bydureon star field of diabetes. Bydureon potential global sales of 10 million to 60 million, w